ATE353107T1 - Abhängigkeit des symptomfreien überlebens 5-fu behandelter darmkrebspatienten vom verhältnis der mrna-expressionshöhe aus thymidinphosphorylase und dihydropyrimidindehydrogenase - Google Patents
Abhängigkeit des symptomfreien überlebens 5-fu behandelter darmkrebspatienten vom verhältnis der mrna-expressionshöhe aus thymidinphosphorylase und dihydropyrimidindehydrogenaseInfo
- Publication number
- ATE353107T1 ATE353107T1 AT04020100T AT04020100T ATE353107T1 AT E353107 T1 ATE353107 T1 AT E353107T1 AT 04020100 T AT04020100 T AT 04020100T AT 04020100 T AT04020100 T AT 04020100T AT E353107 T1 ATE353107 T1 AT E353107T1
- Authority
- AT
- Austria
- Prior art keywords
- mrna expression
- ratio
- symptom
- dependence
- expression level
- Prior art date
Links
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 title abstract 4
- 229960002949 fluorouracil Drugs 0.000 title abstract 4
- 101710132082 Pyrimidine/purine nucleoside phosphorylase Proteins 0.000 title abstract 2
- 102000013537 Thymidine Phosphorylase Human genes 0.000 title abstract 2
- 206010009944 Colon cancer Diseases 0.000 title 1
- 102100022334 Dihydropyrimidine dehydrogenase [NADP(+)] Human genes 0.000 title 1
- 108010066455 Dihydrouracil Dehydrogenase (NADP) Proteins 0.000 title 1
- 208000029742 colonic neoplasm Diseases 0.000 title 1
- 230000004083 survival effect Effects 0.000 title 1
- 208000024891 symptom Diseases 0.000 title 1
- 108020004999 messenger RNA Proteins 0.000 abstract 2
- 101710088194 Dehydrogenase Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03018783 | 2003-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE353107T1 true ATE353107T1 (de) | 2007-02-15 |
Family
ID=34259138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04020100T ATE353107T1 (de) | 2003-08-28 | 2004-08-25 | Abhängigkeit des symptomfreien überlebens 5-fu behandelter darmkrebspatienten vom verhältnis der mrna-expressionshöhe aus thymidinphosphorylase und dihydropyrimidindehydrogenase |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050100936A1 (de) |
| EP (1) | EP1510588B1 (de) |
| JP (1) | JP4032047B2 (de) |
| AT (1) | ATE353107T1 (de) |
| CA (1) | CA2479446C (de) |
| DE (1) | DE602004004571T2 (de) |
| ES (1) | ES2279266T3 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE477339T1 (de) * | 2005-05-31 | 2010-08-15 | Dako Denmark As | Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung |
| DE102006037158A1 (de) * | 2006-08-02 | 2008-02-14 | Bioxsys Gmbh | Verfahren zur Feststellung der Sensitivität von Tumoren gegenüber Capecitabin und Testkit |
| RU2367489C1 (ru) * | 2008-05-26 | 2009-09-20 | Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН | Способ лечения рака прямой кишки |
| GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
| RU2398608C1 (ru) * | 2009-05-13 | 2010-09-10 | Федеральное государственное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Федерального агентства по высокотехнологичной медицинской помощи" | Способ лечения рака прямой кишки |
| WO2011052748A1 (ja) * | 2009-10-30 | 2011-05-05 | 学校法人慶應義塾 | 抗がん剤の感受性判定方法 |
| EP2495569B1 (de) * | 2009-10-30 | 2016-06-15 | Keio University | Verfahren zur bestimmung der empfindlichkeit für ein antikrebsmittel |
| WO2011157678A1 (en) * | 2010-06-14 | 2011-12-22 | Qiagen Gmbh | Method for determination of target cells or tissue for extraction of biomolecules from fixed biological samples |
| ES2393984B1 (es) * | 2011-02-24 | 2013-11-21 | Servicio Andaluz De Salud | Método de obtención de datos útiles para evaluar la respuesta al tratamiento con 5-fluorouracilo (5-FU) |
| EP3067698A1 (de) | 2015-03-11 | 2016-09-14 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Pd-ecgf als biomarker für krebs |
| EP3329244B1 (de) | 2015-07-30 | 2022-10-05 | Qiagen GmbH | Verfahren zur herstellung einer gefrorenen biologischen probe |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19837391A1 (de) * | 1997-08-22 | 1999-02-25 | Hoffmann La Roche | Immunologische Materialien und Verfahren zum Nachweis von Dihydropyrimidindehydrogenase |
| US7005278B2 (en) * | 2001-03-02 | 2006-02-28 | Danenberg Kathleen D | Method of determining dihydropyrimidine dehydrogenase gene expression |
-
2004
- 2004-08-25 EP EP04020100A patent/EP1510588B1/de not_active Expired - Lifetime
- 2004-08-25 ES ES04020100T patent/ES2279266T3/es not_active Expired - Lifetime
- 2004-08-25 DE DE602004004571T patent/DE602004004571T2/de not_active Expired - Lifetime
- 2004-08-25 CA CA2479446A patent/CA2479446C/en not_active Expired - Lifetime
- 2004-08-25 AT AT04020100T patent/ATE353107T1/de not_active IP Right Cessation
- 2004-08-26 US US10/927,669 patent/US20050100936A1/en not_active Abandoned
- 2004-08-26 JP JP2004247413A patent/JP4032047B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2479446A1 (en) | 2005-02-28 |
| JP2005073698A (ja) | 2005-03-24 |
| ES2279266T3 (es) | 2007-08-16 |
| DE602004004571T2 (de) | 2007-11-08 |
| CA2479446C (en) | 2013-05-07 |
| EP1510588A1 (de) | 2005-03-02 |
| DE602004004571D1 (de) | 2007-03-22 |
| EP1510588B1 (de) | 2007-01-31 |
| US20050100936A1 (en) | 2005-05-12 |
| JP4032047B2 (ja) | 2008-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004004571D1 (de) | Abhängigkeit des symptomfreien Überlebens 5-FU behandelter Darmkrebspatienten vom Verhältnis der mRNA-Expressionshöhe aus Thymidinphosphorylase und Dihydropyrimidindehydrogenase | |
| ATE396731T1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| EP1936376A3 (de) | Screening und Behandlungsverfahren zur Vorbeugung von Frühgeburten | |
| WO2003035904A3 (en) | Methods and compositions to evaluate antibody treatment response | |
| BRPI0410296A (pt) | sistema e método para a determinação da eficácia de tratamento de distúrbios neurológicos utilizando o eletroencefalograma | |
| DE60325404D1 (de) | Gerät zur bestimmung der dialyse-effizienz | |
| WO2005100392A3 (en) | Treatment of neuropathic pain with zinc finger proteins | |
| EA201000897A1 (ru) | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты | |
| DE602004024374D1 (de) | Zusammensetzungen zur verwendung als protein-kinase-inhibitoren | |
| DE60324925D1 (de) | Ace2-aktivierung zur behandlung von herz, lungen, und nierenkrankheit und bluthochdruck | |
| ATE450622T1 (de) | Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit | |
| DE60137635D1 (de) | Verwendung von allopurinol zur behandlung von bluthochdruck | |
| WO2002070750A3 (en) | Method of determining dihydropyrimidine dehydrogenase gene expression | |
| NO20054744L (no) | Behandling av Alzheimers sykdom | |
| SE0102147D0 (sv) | New methods | |
| WO2005005661A3 (en) | Genes regulated in ovarian cancer as prognostic and therapeutic targets | |
| NO20020829L (no) | Ny anvendelse av docetaxel for behandling av hepatoma | |
| ATE527377T1 (de) | Erstellung von genexpressionprofilen aus ffpe- proben | |
| EA200600402A1 (ru) | Клеточные стенки дрожжей для лечения или профилактики гипергликемии или для стабилизации уровня сахара в крови | |
| BRPI0407213A (pt) | Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados | |
| BR0315344A (pt) | Métodos para prever edema como um efeito colateral do tratamento com drogas | |
| BRPI0518795A2 (pt) | mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio | |
| JP2006517670A5 (de) | ||
| TR200601622A2 (tr) | Otomatik Üst Çene Genişleticisi | |
| DE602005018840D1 (de) | 3'-modifizierte oligonukleotide mit pseudoisocytosin-nukleobasenderivaten sowie deren anwendungen als primer oder sonden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |